Literature DB >> 8328385

Long-term echocardiographic follow-up of acromegalic heart disease.

J Hradec1, J Marek, J Kral, T Janota, J Poloniecki, M Malik.   

Abstract

Heart muscle disease in acromegaly manifests usually as cardiac hypertrophy. Based on a retrospective analysis, it was suggested that cardiac hypertrophy is slowly reversible after normalization of plasma growth hormone levels. The reversibility of acromegalic heart muscle disease during and after treatment of acromegaly was studied prospectively. A cohort of 78 patients was examined echocardiographically in 1981, and 38 survivors of this group were reexamined 10 years later. Patients were classified according to original hormonal activity in 1981, and change in hormonal activity during follow-up into the following 4 groups: group I--hormonally inactive for entire follow-up (n = 10); group II--hormonally active for entire follow-up (n = 11); group III--initially hormonally inactive with later resurgence (n = 6); and group IV--initially hormonally active with later normalization of growth hormone levels (n = 11). No significant echocardiographic changes occurred during follow-up in group I. Left ventricular posterior wall and septal diastolic thickness, and left ventricular mass increased significantly (all p < 0.05) in group II. Left ventricular posterior wall thickness, mass and diastolic volume increased significantly (p < 0.05, < 0.01 and < 0.001, respectively) in group III. On the contrary, there were significant decreases in left ventricular mass, and both diastolic and systolic left ventricular volumes (p < 0.01, < 0.05 and < 0.05, respectively) in group IV. It is concluded that both hypertrophy and dilatation of the left ventricle in acromegaly are slowly reversible after successful treatment. On the contrary, continuing or relapsed hyperproduction of growth hormone causes further deterioration of acromegalic heart disease.

Entities:  

Mesh:

Year:  1993        PMID: 8328385     DOI: 10.1016/0002-9149(93)90161-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Doppler echocardiographic patterns in patients with acromegaly.

Authors:  M Terzolo; L Avonto; C Matrella; R Pozzi; S Luceri; G Borretta; F Pecchio; G Ugliengo; G P Magro; G Reimondo
Journal:  J Endocrinol Invest       Date:  1995-09       Impact factor: 4.256

2.  Left ventricular volume and mass in children on growth hormone therapy compared with untreated children.

Authors:  D Heuschmann; O Butenandt; M Vogel
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

3.  Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage.

Authors:  N Ozbey; A Oncül; Z Buğra; A Vural; F Erzengin; Y Orhan; K Büyüköztürk; E Sencer; S Molvalilar
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 4.  Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.

Authors:  Ajay N Sharma; Marilyn Tan; Ezra A Amsterdam; Gagan D Singh
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

Review 5.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 6.  Pharmacological therapy for acromegaly: a critical review.

Authors:  Alex F Muller; Aart Jan Van Der Lely
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.